Dapsone is a medication used in combination with rifampicin and clofazimine as multidrug therapy for the treatment of leprosy. It is also used as second-line treatment for prophylaxis against Pneumocystis pneumonia caused by Pneumocystis jirovecii in HIV patients. Dapsone is a competitive antagonist of para-aminobenzoic acid (PABA) and thus, inhibits normal bacterial utilization of PABA for folic acid synthesis. Dapsone is a sulfone active bactericidal and bacteriostatic agent against Mycobacterium leprae. Its mechanism of action is likely similar to that of the sulfonamides, which involves inhibition of folic acid synthesis in susceptible organisms.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.